Severe intraocular pressure response to periocular or intravitreal steroid treatment in Australia and New Zealand: data from the Australian and New Zealand Ophthalmic Surveillance Unit

2014 ◽  
Vol 43 (3) ◽  
pp. 234-238 ◽  
Author(s):  
Jude T Fitzgerald ◽  
Lynda Saunders ◽  
Bronwyn Ridge ◽  
Andrew JR White ◽  
Ivan Goldberg ◽  
...  



1993 ◽  
Vol 9 (2) ◽  
pp. 157-165 ◽  
Author(s):  
JIMMY D. BARTLETT ◽  
BARRY HORWITZ ◽  
ROBERT LAIBOVITZ ◽  
JOHN F. HOWES


1995 ◽  
Vol 27 (4) ◽  
pp. 243-248 ◽  
Author(s):  
Yong Yeon Kim ◽  
Tae Soo Lee


2019 ◽  
Author(s):  
Hiroyuki Yazu ◽  
Dai Miyazaki ◽  
Hiroshi Fujishima

Abstract BACKGROUND: To examine the efficacy of 0.1% tacrolimus eye drops in the treatment of noninfectious, non-necrotizing anterior scleritis. METHODS: This prospective, single-arm study included nine patients (4 males and 5 females; mean age = 59.4 years, standard deviation = 10.5) with anterior scleritis. All patients were first treated with steroids for 1 month and then switched to tacrolimus eye drops alone. We defined baseline as the initiation of steroid or tacrolimus eye drops. Hyperemia and pain were scored before each treatment, at 1 and 2 weeks, and at 1 month after initiation of each treatment by using 5 grades (0 = none; 1+ = mild; 2+ = moderate; 3+ = severe; 4+ = extremely severe). Intraocular pressure (IOP) was also measured from baseline to 6 months after initiating tacrolimus eye drops. Safety was assessed based on the severity and the incidence of adverse events. RESULTS: The scores of hyperemia and pain had significantly decreased from baseline by 1 week after initiating tacrolimus eye drops (both P < 0.05). No significant reduction was observed with steroid treatment throughout the 1-month period in terms of both scores. Tacrolimus eye drops elicited statistically significant differences in mean IOP over the course of treatment (P = 0.02). No additional medications were required to provide relief in any of the patients receiving tacrolimus treatment. No patient had infectious adverse events after initiation of tacrolimus treatment. CONCLUSIONS: Topical tacrolimus may effectively and immediately reduce clinical signs and symptoms of noninfectious, non-necrotizing anterior scleritis. TRIAL REGISTRATION: This trial was prospectively registered on 16/10/2015 under the number (UMIN000034460).



Ophthalmology ◽  
2003 ◽  
Vol 110 (4) ◽  
pp. 831-834 ◽  
Author(s):  
Ronit Friling ◽  
Dov Weinberger ◽  
Abraham Zeharia ◽  
Moshe Lusky ◽  
Marc Mimouni ◽  
...  


Author(s):  
Jesús Vera ◽  
Beatriz Redondo ◽  
Alejandro Perez-Castilla ◽  
George-Alex Koulieris ◽  
Raimundo Jiménez ◽  
...  


2019 ◽  
Vol 9 ◽  
Author(s):  
Eliška Najmanová ◽  
František Pluháček ◽  
Michal Botek ◽  
Jakub Krejčí ◽  
Jana Jarošová


Sign in / Sign up

Export Citation Format

Share Document